Pro-905, a Novel Purine Antimetabolite, Combines with Glutamine Amidotransferase Inhibition to Suppress Growth of Malignant Peripheral Nerve Sheath Tumor
Authors:
- Kathryn M. LembergKLKathryn M. Lemberg
- Eunus S. AliEunus S. Ali
- Marcela KrecmerovaMKMarcela Krecmerova
- Joanna Marie H. AguilarJAJoanna Marie H. Aguilar
- Jesse AltJAJesse Alt
- Diane E. PetersDPDiane E. Peters
- Liang ZhaoLZLiang Zhao
- Ying WuYWYing Wu
- Naziba NuhaNNNaziba Nuha
- John M. AsaraJohn M. Asara
- Verena StaedtkeVSVerena Staedtke
- Christine A. PratilasCPChristine A. Pratilas
Open Access
- 24 August 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12) , 1390-1403
Abstract
Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive soft-tissue sarcomas that arise from neural tissues and carry a poor prognosis. Previously, we found that the glutamine amidotransferase inhibitor JHU395 partially impeded tumor growth in preclinical models of MPNST. JHU395 inhibits de novo purine synthesis in human MPNST cells and murine tumors with partial decreases in purine monophosphates. On the basis of prior studies showing enhanced efficacy when glutamine amidotransferase inhibition was combined with the antimetabolite 6-mercaptopurine (6-MP), we hypothesized that such a combination would be efficacious in MPNST. Given the known toxicity associated with 6-MP, we set out to develop a more efficient and well-tolerated drug that targets the purine salvage pathway. Here, we report the discovery of Pro-905, a phosphoramidate protide that delivered the active nucleotide antimetabolite thioguanosine monophosphate (TGMP) to tumors over 2.5 times better than equimolar 6-MP. Pro-905 effectively prevented the incorporation of purine salvage substrates into nucleic acids and inhibited colony formation of human MPNST cells in a dose-dependent manner. In addition, Pro-905 inhibited MPNST growth and was well-tolerated in both human patient-derived xenograft (PDX) and murine flank MPNST models. When combined with JHU395, Pro-905 enhanced the colony formation inhibitory potency of JHU395 in human MPNST cells and augmented the antitumor efficacy of JHU395 in mice. In summary, the dual inhibition of the de novo and purine salvage pathways in preclinical models may safely be used to enhance therapeutic efficacy against MPNST.Keywords
All Related Versions
Funding Information
- CureSearch for Children's Cancer
- TEDCO Maryland Innovation Initiative
- Allegheny Health Network
- National Institutes of Health (R01NS103927)
- National Institutes of Health (R01CA229451)
- National Institutes of Health (T32 OD011089)
- Neurofibromatosis Therapeutic Acceleration Program
- National Institutes of Health (R01GM135587)
- National Institutes of Health (R01GM143334)
- LAM Foundation (LAM0151E01-22)
- Czech National Node to the European Infrastructure for Translational Medicine EATRIS-CZ (LM2023053)
This publication has 56 references indexed in Scilit:
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C VirusJournal of Medicinal Chemistry, 2010
- Linear and convergent approaches to 2-substituted adenosine-5′-N-alkylcarboxamidesTetrahedron, 2009
- Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancerNature Reviews Cancer, 2008
- Dose translation from animal to human studies revisitedThe FASEB Journal, 2007
- Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine PharmacodynamicsCancer Research, 2007
- Thiopurines, DNA damage, DNA repair and therapy-related cancerBritish Medical Bulletin, 2006
- Mouse Models of Tumor Development in Neurofibromatosis Type 1Science, 1999
- A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumorsCancer Chemotherapy and Pharmacology, 1990
- Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.British Journal of Clinical Pharmacology, 1983